Research programme: neurological therapies - Eisai/Johns Hopkins University

Drug Profile

Research programme: neurological therapies - Eisai/Johns Hopkins University

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins Brain Science Institute
  • Developer Eisai Inc; Johns Hopkins Brain Science Institute
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurological disorders

Most Recent Events

  • 31 May 2017 Small molecule glutamate carboxypeptidase II (GCPII) inhibitors is still in early research for Neurological disorders in USA
  • 31 May 2017 Small molecule glutamate carboxypeptidase II inhibitors licensed to Eisai for Neurological disorders
  • 17 Oct 2011 Early research in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top